Previous Close | 3.58 |
Open | 3.65 |
Bid | 2.80 x 100 |
Ask | 4.00 x 1000 |
Day's Range | 3.50 - 3.70 |
52 Week Range | 2.75 - 6.90 |
Volume | 43,212 |
Avg. Volume | 80,174 |
Market Cap | 113.104M |
Beta | 0.89 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.12 |
Earnings Date | May 15, 2018 - May 21, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.13 |
As of late, it has definitely been a great time to be an investor in ProQR Therapeutics N.V. (PRQR)
Peter A. Beal joins ProQR’ s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field ...
LEIDEN, the Netherlands, April 03, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
LEIDEN, the Netherlands, March 05, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
The Leiden, Netherlands-based company said it had a loss of 46 cents per share. For the year, the company reported that its loss widened to $49.3 million, or $1.94 per share. The company's shares closed ...
Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase ...
LEIDEN, the Netherlands, Feb. 27, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
After looking at ProQR Therapeutics NV.’s (NASDAQ:PRQR) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2 A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness ...
How Is Vertex Pharmaceuticals Positioned after 4Q17?
LEIDEN, the Netherlands, Feb. 06, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
On a per-share basis, the Leiden, Netherlands-based company said it had a loss of 49 cents. The company's shares closed at $3.10. A year ago, they were trading at $4.75. _____ This story was generated ...